Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

Fig. 4

Impact of PAVD use on iVDPV prevalence for different PAVD use scenarios starting on January 1, 2020, based on the first 100 stochastic iterations of the DES model. a Lower bound on effectiveness of a single PAVD compound (i.e., assuming 40 % of recipients recover from infection). b Hypothetical upper bound on effectiveness of one or more PAVD compounds (i.e., assuming 90 % of recipients recover from infection)

Back to article page